Aarti Drugs Ltd

The company's financial performance shows significant weakness and volatility. While the 10-year compounded sales growth is a modest 8%, more recent figures show a considerable slowdown, with the 3-year compounded rate at -2%. Annual sales for March 2024 declined by 6.9% year-over-year. Profit growth is also a concern, with a negative 5-year compounded growth of -7%. Although the TTM profit growth was 3%, this follows years of volatility, including contractions of -27% and -19% in FY22 and FY23, respectively. Operating Profit Margins (OPM) have deteriorated from a peak of 20% in 2021 to 13% in FY24, below the historical 10-year average of around 15-16%. This combination of slowing sales, volatile profits, and compressing margins points to underlying challenges in core operations. On a positive note, profits are primarily from core operations, as other income contributes minimally to the Profit Before Tax.

Capital efficiency and returns have been on a consistent decline. The Return on Capital Employed (ROCE) has fallen sharply from a high of 34% in FY21 to 15% in FY24, with the current reported ROCE at 13.53%. This is significantly below the company's historical performance. Similarly, Return on Equity (ROE) shows a clear downward trend across all timeframes; the 10-year compounded average of 18% has dropped to 13% for both the 3-year period and the last fiscal year. This trend suggests shareholder funds are yielding progressively lower returns. The Asset Turnover ratio also decreased from 1.13 in FY22 to 1.04 in FY24, indicating less efficient use of assets to generate revenue. The only positive operational metric is the Cash Conversion Cycle, which improved from 123 days to 115 days in the last year, showing better working capital management.

The company maintains a healthy balance sheet and demonstrates financial prudence. The Debt to Equity ratio stood at a conservative 0.44 in March 2024, an improvement from 0.51 in the previous year. A key strength is the Interest Coverage Ratio, which was a robust 8.4x in March 2024. While lower than the peaks of FY21 (16.9x) and FY22 (13.8x), this level indicates that operating profit comfortably covers interest expenses. This financial stability provides a crucial buffer, especially given the weaknesses in growth and profitability. The company has also been consistent in sharing profits with shareholders, maintaining a dividend payout ratio of around 5-6% in recent years. While the payout percentage is modest, its consistency is a positive signal.

The shareholding structure presents a conflicting narrative. A significant concern is the steady decline in promoter holding, which has decreased from 62.46% in March 2017 to 57.13% in March 2024. This consistent reduction by the core ownership group can be interpreted as a potential signal of weakening confidence in long-term prospects. In contrast, institutional investors have shown increasing interest. Foreign Institutional Investors (FIIs) increased their stake from 1.94% to 2.56% in the year ending March 2024. More significantly, Domestic Institutional Investors (DIIs) raised their holding from 4.09% to 5.99% over the same period. This growing institutional ownership suggests that professional fund managers see value in the company, which acts as a counterbalance to the declining promoter stake. The overall picture is therefore mixed.

A potential accounting quality concern arises from the historical mismatch between reported profits and actual cash generated. For three consecutive fiscal years (FY21, FY22, FY23), the Cash Flow from Operations (CFO) was substantially lower than the Net Profit. In FY22, the company reported a Net Profit of ₹205 Cr but generated only ₹70 Cr in CFO. Such a divergence can indicate issues with working capital management or aggressive revenue recognition. Although the situation reversed in FY24, with CFO at ₹359 Cr far exceeding the Net Profit of ₹172 Cr, the persistent negative trend in prior years remains a point of concern regarding the quality of past earnings.